checkpoint inhibitors

Scancell picks winner from phase 2 cancer vaccine face-off

Scancell linked iSCIB1+ to a 69% response rate in advanced melanoma, leading the biotech to pick the next-generation candidate over its older sibling.

Nick Paul Taylor Jul 22, 2025 9:38am

Hummingbird uses VISTA buzz to secure $290M pact for tumor drug

Jun 26, 2025 4:53am

Graphic of a puzzle depicting both the US and Chinese flags with missing pieces bridging the two together

Pfizer CEO makes case for $6B bet on 'fabulous' bispecific

Jun 10, 2025 9:56am

Close-up of Benjamin Franklins eyes peering through hundred dollar bills

BMS inks $11B biobucks BioNTech deal to join bispecific rush

Jun 2, 2025 8:59am

Immutep's LAG-3 agent posts 'impressive' survival data

May 5, 2025 10:37am

White arrow on a road pointing to the rising sun

Pfizer ties PD-1 drug to 32% cancer risk reduction in phase 3

Apr 28, 2025 7:25am